University of Texas Roundtable on Recent Trends in U.S. Venture Capital

• DOI: http://doi.org/10.1111/jacf.12191
• Author: Brooks Gibbins,Venu Shamapant,Ken Wiles,Jake Saper,Glenn Schiffman
• Published date: 01 September 2016
• Date: 01 September 2016

In This Issue: Active Investors and Valuation

Columbia Business School Centennial Roundtable

The Achievements and Future of Business Education

8Glenn Hubbard, Columbia Business School; Geoff Garrett,

Wharton School of Business; Nitin Nohria, Harvard Business

School; and Garth Saloner, Stanford Business School.

Moderated by Jan Hopkins

Columbia Business School Centennial Roundtable

Value Creation by Active Investors (and Its Potential for Addressing Social Problems)

26 Russ Carson, Welsh, Carson, Anderson, and Stowe; and

Paul Hilal, PCH Capital. Moderated by Trevor Harris,

Columbia Business School

University of Texas Roundtable

Recent Trends in U.S. Venture Capital

36 Brooks Gibbens, FinTech Collective; Jake Saper,

Emergence Capital; Glenn Schiffman,Guggenheim; and

Venu Shemapant, LiveOak Venture Partners.

Moderated by Ken Wiles, University of Texas at Austen.

Drivers of Shareholder Returns in Tech Industries

(or How to Make Sense of Amazon’s Market Value)

48 Gregory V. Milano, Arshia Chatterjee, and David Fedigan,

Fortuna Advisors LLC

Private Equity, the Rise of Unicorns, and the Reincarnation of

Control-based Accounting

56 Jerold L. Zimmerman, University of Rochester

A Better Way to Measure Operating Performance

(or Why the EVA Math Really Matters)

68 Stephen F. O’Byrne, Shareholder Value Advisors

Estimating the Cost of Capital Using Stock Prices and Near-term Earnings Forecasts 87 Peter Easton, University of Notre Dame

What Cost of Capital Should You Use? The Market Has an Answer 95 Leon Zolotoy and Andrew John, Melbourne Business School

Do Investment Banks Have Incentives to Help Clients

Make Value-Creating Acquisitions?

103 John J. McConnell, Purdue University, and Valeriy Sibilkov,

University of Wisconsin-Milwaukee

Valuation of a Developmental Drug as a Real Option 118 John Lynch and Richard Shockley, Indiana University

VOLUME 28 | NUMBER 3 | SUMMER 2016

APPLIED CORPORATE FINANCE

Journal of